The distinguished roles of ANKRD11 in Ki67-high and -low group suggest a strong disturbance of Ki67 related pathway to ANKRD11 function and highlight the necessity of restrictive administration of HDAC3 inhibitor in luminal A breast cancer. This evidence concerns the gene HDAC3 and breast carcinoma.